Literature DB >> 17352518

Sitagliptin: a viewpoint by Itamar Raz.

Itamar Raz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17352518     DOI： 10.2165/00003495-200767040-00008

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  3 in total

1.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Authors:  H C Gerstein; S Yusuf; J Bosch; J Pogue; P Sheridan; N Dinccag; M Hanefeld; B Hoogwerf; M Laakso; V Mohan; J Shaw; B Zinman; R R Holman
Journal:  Lancet       Date:  2006-09-23       Impact factor: 79.321

2.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Authors:  Bernard Charbonnel; Avraham Karasik; Ji Liu; Mei Wu; Gary Meininger
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

3.  The U.K. Prospective Diabetes Study. A review.

Authors:  R C Turner
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.